STOCK TITAN

Regulus Therapeutics Inc - RGLS STOCK NEWS

Welcome to our dedicated news page for Regulus Therapeutics (Ticker: RGLS), a resource for investors and traders seeking the latest updates and insights on Regulus Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Regulus Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Regulus Therapeutics's position in the market.

Rhea-AI Summary
Regulus Therapeutics Inc. (RGLS) announces positive topline data from the Phase 1b MAD Clinical Trial of RGLS8429 for ADPKD, along with an oversubscribed $100 million private placement. The company completed the third cohort enrollment and anticipates data in mid-2024. A Type D Meeting with the FDA discussed an accelerated approval pathway for RGLS8429.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
earnings
-
Rhea-AI Summary
Regulus Therapeutics Inc. (RGLS) has entered into a definitive securities purchase agreement for a private placement with institutional and accredited investors. The oversubscribed financing includes participation from various investors, indicating strong market interest.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
71.01%
Tags
none
-
Rhea-AI Summary
Regulus Therapeutics Inc. announces positive topline results from Phase 1b MAD study of RGLS8429 for ADPKD treatment. Mechanistic dose response observed at 2mg/kg dose level. Cohort 3 fully enrolled with data readout in mid-2024. Company plans to increase sample size for cohort 4. FDA meeting confirms potential for accelerated approval pathway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
71.01%
Tags
clinical trial
Rhea-AI Summary
Regulus Therapeutics Inc. (Nasdaq: RGLS) completes enrollment in the third cohort of patients in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. The company expects topline data from the second cohort in Q1 2024, topline data from the third cohort in mid-2024, and the initiation of the fourth cohort in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Regulus Therapeutics Inc. (RGLS) announced CEO Jay Hagan's participation in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023, at 10:25 a.m. ET. The live presentation replay will be available on the company's investor relations website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.11%
Tags
conferences
-
Rhea-AI Summary
RGLS - Regulus Therapeutics Announces Positive Topline Data from Phase 1b Clinical Trial for RGLS8429 in ADPKD Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
earnings
Rhea-AI Summary
Regulus Therapeutics Inc. (Nasdaq: RGLS) has announced the dosing of the first patient in the third cohort of the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. The Phase 1b MAD study is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of RGLS8429 in adult patients with ADPKD. The study will evaluate RGLS8429 treatment across three different dose levels and measure changes in polycystins, height-adjusted total kidney volume, cyst architecture, and overall kidney function. The second cohort is being dosed at 2 mg/kg of RGLS8429 or placebo every other week for three months. No issues were identified in cohort two, allowing advancement to cohort three. The third cohort will receive 3 mg/kg of RGLS8429 or placebo every other week for three months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
clinical trial
-
Rhea-AI Summary
Regulus Therapeutics announces advancement to third cohort in Phase 1b MAD study of RGSL8429 for ADPKD treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.61%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.7%
Tags
clinical trial
Regulus Therapeutics Inc

Nasdaq:RGLS

RGLS Rankings

RGLS Stock Data

188.54M
41.55M
1.41%
43.63%
7.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About RGLS

regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg